RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialResearch in context

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialResearch in context

Summary: Background: Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8+ T-cell infiltratio...

Full description

Bibliographic Details
Main Authors: Qihan Fu, Yi Zheng, Weijia Fang, Qingwei Zhao, Peng Zhao, Lulu Liu, You Zhai, Zhou Tong, Hangyu Zhang, Meihua Lin, Xudong Zhu, Huamao Wang, Yumeng Wang, Zhen Liu, Daijing Yuan, Xuanwen Bao, Wanwan Gao, Xiaomeng Dai, Zonghai Li, Tingbo Liang
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:EClinicalMedicine
Subjects:
CAR T-cell therapy
Hepatocellular carcinoma
Safety of CAR T-cell therapy in HCC
GPC3-targeted CAR T cells
Immunotherapy for advanced HCC
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003528

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003528

Similar Items